Breaking News

You are here » Indian-Commodity  :  IPO  :  Fine Organic Industries files DRHP with SEBI for IPO

09-Feb2018

Fine Organic Industries files DRHP with SEBI for IPO

Fine Organic Industries has filed draft red herring prospectus (DRHP) with the market regulator Securities and Exchange Board of India (SEBI) to float its initial public offering (IPO). The equity shares are proposed to be listed on BSE and NSE.

The IPO will see sale of up to 76,64,994 equity shares by the existing shareholders. The listing will enhance its brand name and provide liquidity to the existing shareholders.

JM Financial and Edelweiss Financial Service are book running lead managers to the issue.

Fine Organic Industries is a leading producer of speciality additives for foods, plastics, rubbers, paints, inks, cosmetics, coatings, textile auxiliaries, lubes and several other speciality applications.


Related News

View all news

Spandana Sphoorty gets SEBI's nod for IPO

Spandana Sphoorty Financial has received markets regulator Securities and Exchange Board of India's (SEBI) approval to raise funds through an initial public offering (IPO). The IPO consists of fresh issue......

Bharat Hotels gets SEBI's approval for IPO

Bharat Hotels has received markets regulator Securities and Exchange Board of India's (SEBI) approval to raise funds through an initial public offering (IPO). The IPO comprises sale of fresh equity shares......

Chartered Speed files DRHP with SEBI for public issue

Fleet bus operators Chartered Speed has filed draft red herring prospectus (DRHP) with the market regulator Securities and Exchange Board of India (SEBI) to raise an estimated Rs 273 crore through an Initial......

Top News

View all news

Bhansali Engineering Polymers reports 33% fall in Q2 net profit

Bhansali Engineering Polymers has reported results for second quarter ended September 30, 2018.The company has reported 32.71% fall in its net profit at Rs 16.89 crore for the quarter under review as compared......

Biocon, Mylan N.V. receive positive CHMP opinion for Ogivri

Biocon and Mylan N.V. have announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ogivri, a biosimilar......

Lupin Neurosciences receives positive CHMP opinion for NaMuscla

Lupin Neurosciences, a specialty pharma division of Lupin has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA),......